S100P and prostate carcinoma: It should be mentioned that there has been a conflicting report showing a degree of negative correlation with prostate cancer progression on human samples obtained prior to any hormonal treatment [58], and that S100P has been identified as a differential diagnostic marker of urothelial carcinomas of the bladder, concerning cases where the tumor mass is difficult to differentiate from a similarly advanced prostate cancer [59].